CORDIS
EU research results

CORDIS

English EN
Microscopy of living cancer cells at physiological oxygen levels: the MICROX platform

Microscopy of living cancer cells at physiological oxygen levels: the MICROX platform

Objective

Functional evaluation of bioactive compounds using cell-based assays is key in discovering new and improved drugs to address our societies growing medical needs. In a large number of academic and private R&D facilities around the world, hi-content microscopy screening is used to complement and often outperform the conventional luminescence and fluorescence plate-reader assays. The combination of fluorescent-probe technology, modern optical microscopes and innovative functional assays allows monitoring highly dynamic events in living cells with exquisite temporal and spatial resolution.
Remarkably, drug candidates and treatment regimens are commonly tested on living cells maintained at atmospheric oxygenation levels (i.e., at 21% O2) while in reality, cells in our bodies never experience such high oxygen levels. Rather, most cells experience 2-5% of O2 and cancer cells in solid tumours are generally hypoxic, i.e., they function at < 1% of O2. It has become evident that oxygenation of the preparation dramatically affects efficacy of our drugs, in particular of cancer treatments. Thus, there is an urgent need to establish functional microscopy assays for (cancer)drug efficacy at hypoxic conditions.
However, it is not trivial to enclose the necessary high-end microscopes in O2-tight incubators while maintaining good access to the cells. In this project, experienced biochemist and pharmacologist dr. Olga Mazina aims to team up with the advanced microscopy group of prof. Kees Jalink to establish an innovative MICROX microscopy platform with fully adjustable atmospheric conditions, along with a panel of biosensors optimized for use at hypoxia. MICROX will be developed in close collaboration with leading European manufacturers and validated in studies addressing cancer cell signalling and sensitivity to cancer drugs at various O2 levels.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Address

Plesmanlaan 121
1066 Cx Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 281 358,72

Project information

Grant agreement ID: 840088

Status

Grant agreement signed

  • Start date

    15 September 2019

  • End date

    14 September 2022

Funded under:

H2020-EU.1.3.2.

  • Overall budget:

    € 281 358,72

  • EU contribution

    € 281 358,72

Coordinated by:

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands